By Counterforce Health Team in Onpattro (patisiran) —

How to Get Onpattro (Patisiran) Covered by Humana in Florida: Complete Renewal Guide with Appeals Process

Quick Answer: Getting Onpattro Covered by Humana in Florida

Onpattro (patisiran) requires prior authorization from Humana Medicare Advantage and Part D plans in Florida. You'll need genetic confirmation of a TTR mutation, neurologist documentation of hATTR polyneuropathy, and baseline functional assessments (mNIS+7 scores). Submit renewal requests 30-45 days before expiration with updated clinical data showing treatment response. If denied, you have 65 days to appeal with evidence-based documentation. Start by having your neurologist gather genetic test results and submit via Humana's provider portal or fax (877-486-2621).

Table of Contents

  1. Renewal Triggers: When to Start Planning
  2. Evidence Update Requirements
  3. Renewal Packet Essentials
  4. Timeline and Submission Process
  5. If Coverage Lapses
  6. Annual Formulary Changes
  7. Appeals Playbook for Florida
  8. Common Denial Reasons & Solutions
  9. Cost Management Strategies
  10. FAQ

Renewal Triggers: When to Start Planning

Humana typically approves Onpattro for 6-12 month periods initially, requiring renewal with updated clinical evidence. Start your renewal process when you notice these triggers:

Timing Windows:

  • 45 days before expiration: Ideal submission timeframe to avoid gaps
  • 30 days before: Minimum recommended lead time for standard review
  • Emergency renewal: If you're within 7 days of expiration, request expedited review

Clinical Signs to Document Early:

  • Changes in mNIS+7 scores (Modified Neuropathy Impairment Scale+7)
  • New functional limitations or improvements
  • Any adverse events or tolerability issues
  • Changes in weight affecting dosing calculations
Tip: Set a calendar reminder 60 days before your current authorization expires. This gives you buffer time to gather updated documentation.

Evidence Update Requirements

For Onpattro renewal, Humana requires proof that treatment continues to provide clinical benefit for your hATTR polyneuropathy.

Required Clinical Documentation

Functional Assessment Updates:

  • mNIS+7 scores: Baseline vs. current measurements showing disease progression or stabilization
  • 6-Minute Walk Test (6MWT): Distance changes indicating functional capacity
  • Polyneuropathy Disability (PND) Score: Current stage assessment
  • Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) scores if available

Laboratory Monitoring:

  • Platelet count ≥100×10⁹/L (required for continued treatment)
  • Kidney function tests
  • Vitamin A levels (monitor for deficiency with long-term TTR suppression)
  • Updated TTR genetic testing confirmation

Treatment Response Documentation:

  • Neurologist notes on symptom progression or improvement
  • Any hospitalizations or emergency visits related to hATTR
  • Adherence to the every-3-week infusion schedule
  • Documentation of premedication protocol compliance
Note: The VA guidelines recommend continuing therapy only if patients demonstrate positive clinical response including improved motor function, quality of life, or decreased neurological impairment after at least 9 months of treatment.

Renewal Packet Essentials

Your renewal submission must include specific documents to meet Humana's medical necessity criteria.

Core Documents Checklist

  • Previous authorization approval letter (copy of current/expired authorization)
  • Updated neurologist letter addressing treatment response and ongoing need
  • Recent mNIS+7 and functional assessments (within 3-6 months)
  • Laboratory results showing continued safety monitoring
  • Prescription with current dosing based on weight/clinical status
  • Genetic testing confirmation of pathogenic TTR variant (if not previously submitted)

Medical Necessity Letter Structure

Your neurologist's letter should address these key points:

  1. Patient identification and confirmed hATTR-PN diagnosis with ICD-10 code E85.1
  2. Treatment history including previous authorization dates and clinical response
  3. Current functional status with objective measures (mNIS+7, 6MWT results)
  4. Ongoing medical necessity based on disease progression without treatment
  5. Safety monitoring results and plan for continued oversight
  6. Alternative therapy consideration and why Onpattro remains optimal

Timeline and Submission Process

Understanding Humana's review timelines helps you plan effectively and avoid treatment gaps.

Review Type Timeline When to Use Submission Method
Standard Review Up to 30 days Routine renewals Provider portal, fax 877-486-2621
Expedited Review 24-72 hours Health at risk if delayed Phone 800-867-6601 + documentation
Appeal Review 65 days from denial After initial denial Written appeal with evidence

Step-by-Step Submission Process

  1. Verify current authorization status via Humana provider portal
  2. Gather updated clinical documentation (see Evidence Update section)
  3. Complete Humana's PA renewal form with all required fields
  4. Submit via preferred method: Provider portal (fastest) or fax 877-486-2621
  5. Track submission and follow up within 7 days if no acknowledgment
  6. Prepare for potential peer-to-peer review if requested by Humana
  7. Document approval and note new expiration date for future planning

If Coverage Lapses

Despite careful planning, coverage gaps can occur. Here's how to minimize disruption to your Onpattro treatment.

Immediate Actions for Coverage Gaps

Contact Your Healthcare Team:

  • Notify your neurologist immediately about the lapse
  • Request expedited resubmission if the delay was due to missing documentation
  • Ask about temporary bridging options through manufacturer programs

Temporary Coverage Options:

  • Alnylam Assist Program: Contact (1-833-256-9526) for potential bridge therapy support
  • Hospital-based emergency access: For urgent situations, some hospitals can provide emergency doses
  • Medicare Part D exceptions: Request temporary supply while appeal is pending

Financial Considerations:

  • Onpattro costs approximately $450,000-$500,000 annually at list price
  • Without insurance, each infusion costs roughly $9,785 per vial
  • Manufacturer copay assistance may help with out-of-pocket costs during gaps
From our advocates: We've seen patients successfully bridge coverage gaps by working closely with their infusion centers and the manufacturer's patient assistance program. The key is immediate communication when you learn about a lapse—don't wait to see if it resolves on its own.

Annual Formulary Changes

Humana can modify their formulary placement and coverage criteria for Onpattro during the year, affecting your access and costs.

2024-2025 Humana Medicare Changes in Florida

Key Updates:

  • No Part D deductible for many Humana Group MA HMO plans
  • Premium increases: Some Florida plans increased from $47.85 to $75.09 monthly
  • Specialty drug tier placement: Onpattro likely remains Tier 5 (specialty) with high cost-sharing
  • Prior authorization requirements: Continue to require genetic confirmation and specialist evaluation

What to Monitor Annually

October-December (Open Enrollment):

  • Review your plan's updated formulary for Onpattro placement
  • Check if prior authorization requirements have changed
  • Compare costs across available Humana plans in your Florida ZIP code
  • Verify your specialists remain in-network

Monthly Throughout the Year:

  • Humana can remove drugs with 30-day notice (rare for FDA-approved treatments)
  • New restrictions or quantity limits may be added
  • Generic alternatives or biosimilars could affect coverage

Appeals Playbook for Florida

When Humana denies your Onpattro renewal, Florida residents have specific appeal rights under both federal Medicare rules and state insurance regulations.

Internal Appeal Process (First Level)

Timeline: 65 days from denial notice
Method: Written appeal with supporting documentation
Review time: 30 days for standard, 72 hours for expedited

Required Elements:

  • Copy of original denial letter
  • Updated medical necessity letter addressing denial reasons
  • Additional clinical evidence supporting continued need
  • Peer-reviewed literature on Onpattro efficacy for hATTR

External Review (Second Level)

If Humana upholds their denial, Florida residents can request external review through independent medical experts.

Process:

  1. Exhaust internal appeals (required first step)
  2. Request external review within 4 months of final internal denial
  3. Submit via Florida Department of Financial Services (no cost to patient)
  4. Independent medical review by specialists not affiliated with Humana
  5. Binding decision that Humana must follow if overturned

Contact Information:

  • Florida Department of Financial Services: 1-877-MY-FL-CFO (877-693-5236)
  • Online complaint portal: MyFloridaCFO.com
  • Insurance Consumer Helpline for guidance and assistance

Success Strategies for Appeals

Evidence-Based Approach:

  • Address each denial reason point-by-point with clinical data
  • Include updated mNIS+7 scores showing treatment benefit
  • Cite FDA labeling and peer-reviewed studies on hATTR treatment
  • Document functional improvements or disease stabilization

Professional Support: Healthcare coverage advocates like Counterforce Health specialize in turning insurance denials into targeted, evidence-backed appeals. Their platform analyzes denial letters and plan policies to identify the specific basis for denial—whether PA criteria, step therapy, non-formulary status, or "not medically necessary" determinations—then drafts point-by-point rebuttals aligned with the plan's own rules.

Common Denial Reasons & Solutions

Understanding why Humana denies Onpattro requests helps you prepare stronger renewal submissions.

Denial Reason Solution Documentation Needed
Missing genetic confirmation Submit CLIA-certified TTR mutation testing Pathogenic variant report with lab letterhead
Insufficient specialist evaluation Neurologist consultation and ongoing care Detailed notes on hATTR-PN diagnosis and staging
Lack of baseline assessments Complete functional testing before renewal mNIS+7, 6MWT, PND scores with dates
No documented treatment response Show objective improvement or stabilization Comparative scores over time with interpretation
Request for non-FDA uses Clarify indication for polyneuropathy only ICD-10 E85.1 and exclude cardiac amyloidosis
Alternative therapy not tried Document contraindications or failures Prior therapy records with outcomes/tolerability

Cost Management Strategies

Onpattro's high cost makes financial planning essential for long-term treatment success.

Medicare Part D Cost Structure (2025-2026)

Out-of-Pocket Maximum: $2,100 annually (after reaching this, Medicare covers 100%)
Specialty Tier Cost-Sharing: Varies by plan, typically 25-33% of drug cost
Catastrophic Coverage: Available after reaching out-of-pocket maximum

Financial Assistance Options

Manufacturer Support:

  • Alnylam Assist: Copay support and patient assistance programs
  • Bridge therapy: Temporary coverage during insurance transitions
  • Financial counseling: Help navigating insurance and assistance programs

Medicare-Specific Programs:

  • Extra Help (LIS): Low-income subsidy for Part D costs
  • Medicare Savings Programs: State programs to help with premiums and deductibles
  • Supplemental Insurance: Medigap policies may cover additional costs

FAQ

How long does Humana prior authorization take for Onpattro in Florida?
Standard review takes up to 30 days. Expedited review (when health is at risk) takes 24-72 hours. Submit via provider portal or fax 877-486-2621.

What if Onpattro is not on Humana's formulary?
You can request a formulary exception with medical necessity documentation. This process follows the same timeline as prior authorization appeals.

Can I request an expedited appeal if my treatment is interrupted?
Yes, if the delay could seriously harm your health. Your neurologist must certify the urgency, and you can request expedited internal and external reviews simultaneously.

Does step therapy apply if I've been stable on Onpattro?
Generally no. If you have prior authorization history and documented stability, Humana typically doesn't require trying alternatives first during renewal.

What happens if I move to a different Humana plan in Florida?
Your authorization may transfer, but you should verify coverage and resubmit documentation if the new plan has different requirements.

How often do appeals succeed for Onpattro denials?
External appeals have approximately 82% success rates when supported by complete clinical documentation and evidence-based arguments.

Can my infusion center help with the renewal process?
Yes, many specialty pharmacies and infusion centers have prior authorization specialists who can assist with Humana submissions and follow-up.

What if my neurologist is not familiar with Humana's requirements?
Provide them with Humana's specific criteria and consider connecting them with Alnylam Assist's clinical support team for guidance on medical necessity letters.

Personal Renewal Tracker

Use this template to track your Onpattro renewal progress:

Current Authorization Details:

  • Authorization number: _______________
  • Expiration date: _______________
  • Approved dose/frequency: _______________

Renewal Timeline:

  • Start gathering documents: _______________
  • Submit renewal request: _______________
  • Follow-up date: _______________
  • Decision received: _______________

Key Contacts:

  • Neurologist office: _______________
  • Humana PA department: 877-486-2621
  • Alnylam Assist: 1-833-256-9526
  • Florida DFS: 877-693-5236

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual circumstances and plan specifics. Always consult with your healthcare provider and insurance plan directly for personalized guidance. Coverage policies and requirements may change without notice.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.